Risk Factors of Spontaneous Fungal Peritonitis in Cirrhotic Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05117073

Enrollment

100

Registered

2021-11-11

Start date

2021-09-01

Completion date

2023-04-29

Last updated

2023-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontanous Fungal Peritonitis

Keywords

spontanous fungal peritonitis, liver cirrhosis, risk factors

Brief summary

Spontaneous bacterial peritonitis (SBP) is an infection of the peritoneal cavity with no surgically treatable intra-abdominal source of infection. Spontaneous peritonitis is a potentially fatal complication in patients with advanced liver cirrhosis. It is estimated that 10-20 % of patients with cirrhotic ascites may develop spontaneous peritonitis, which is usually caused by a bacterial infection. In contrast, spontaneous fungal peritonitis (SFP) is less well-recognized. SFP may be associated with higher mortality rates than SBP but therapeutic approaches are largely undefined. To this end, the epidemiology and outcomes of patients with SFP have only been documented sporadically aimed to evaluate the risk factors for the development of spontaneous fungal peritonitis (SFP), and the prognosis of SFP compared with SBP

Detailed description

Cross-sectional study Studied population & locality: Patients with signs and symptoms suggestive of spontaneous peritonitis who will be admitted to Tropical medicine and Gastroenterology or Internal medicine departments in Sohag university hospitals during the period from september 2021 to december 2022 will be included in the study. According to the results of ascitic fluid analysis, we will divide the patients into 2 groups: Group (1): patients with spontaneous bacterial peritonitis (SBP). Group (2): patients with spontaneous fungal peritonitis (SFP). Exclusion criteria: Patients seropositive for human immunodeficiency virus (HIV) and patients undergoing continuous ambulatory peritoneal dialysis were excluded from this study. Methods: All included patients will be subjected to: 1. Detailed history, complete general and systemic examination. 2. Ascitic fluid analysis 3. Bacterial and fungal culture from ascitic fluid: 4. Laboratory investigations: Fasting blood sugar Liver function tests. CBC. Ethical considerations:

Interventions

DIAGNOSTIC_TESTASCITIC FLUID CULTURE

Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patients with signs and symptoms suggestive of spontaneous peritonitis who will be admitted to Tropical medicine and Gastroenterology or Internal medicine departments in Sohag university hospitals during the period from September 2021 to december 2022

Exclusion criteria

Patients seropositive for human immunodeficiency virus (HIV) and patients undergoing continuous ambulatory peritoneal dialysis were excluded from this study.

Design outcomes

Primary

Measure	Time frame	Description
he risk factors for the development of spontaneous fungal peritonitis	September 2021 to December 2022 will be included in the study.	number/percentage

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026